Conference Coverage

CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort

Publish date: June 27, 2018

 

REPORTING FROM ASCO 2018

SOURCE: Abramson JS et al. ASCO 2018. Abstract 7505.

Pages

Recommended Reading

British good practice paper offers MCL diagnosis pearls
MDedge Hematology and Oncology
DLBCL survival improved with novel antibody-drug conjugate
MDedge Hematology and Oncology
Ibrutinib sNDA receives priority review
MDedge Hematology and Oncology
T-cell therapy induced CMRs with no CRS
MDedge Hematology and Oncology
Inhibitor exhibits activity in B- and T-cell NHLs
MDedge Hematology and Oncology
Combo proves ‘beneficial’ for ‘unfit’ CLL patients
MDedge Hematology and Oncology
FDA places SB-generated CAR T-cell therapy on clinical hold
MDedge Hematology and Oncology
Peripheral blood MRD correlates with treatment benefit in CLL
MDedge Hematology and Oncology
‘Excellent’ survival with HCT despite early treatment failure in FL
MDedge Hematology and Oncology
Interim PET scans identify HL patients with better outcomes
MDedge Hematology and Oncology